Hay et al.16 evaluated the outcome of phase I/II clinical trial for adults with r/r B-ALL by defined CD4+:CD8+ composition CD19-CD28–4–1BB -CD3z CAR T cells, the median EFS and OS were 7.6 and 20.0 months, respectively6. The gene discussed is CD8A; the disease is acute lymphoblastic leukemia.